# Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma

> **NCT05037669** · PHASE1 · WITHDRAWN · sponsor: **University of Pennsylvania**

## Conditions studied

- Acute Lymphoblastic Leukemia
- Chronic Lymphocytic Leukemia
- Non Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** PACE CART19

## Key facts

- **NCT ID:** NCT05037669
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-07
- **Primary completion:** 2025-01
- **Final completion:** 2038-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No available investigational product
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05037669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05037669, "Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05037669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*